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Abstract
Influence of an intracranial aneurysm (IA) rupture on the expression of miRNAs and the potential significance of the resulting
changes remains poorly understood. We aimed to characterize the response to the IA rupture through the analysis of miRNAs in
peripheral blood cells. Expression of small RNAs was investigated using deep transcriptome sequencing in patients in the acute
phase of an IA rupture (first 72 h), in the chronic phase (3–15 months), and controls. A functional analysis and the potential
interactions between miRNAs and target genes were investigated. We also measured the levels of proteins that were influenced
by regulated miRNAs. We found that 106 mature miRNAs and 90 miRNA precursors were differentially expressed among the
groups. The regulated miRNAswere involved in a variety of pathways, and the top pathway involved cytokine-cytokine receptor
interactions. The identified miRNAs targeted the inflammatory factors HMGB1 and FASLG. Changes in their expression were
detected at the mRNA and protein levels. IA rupture strongly influences the transcription profiles in peripheral blood cells. The
regulated miRNAs were involved in the control of immune cell homeostasis. In summary, these results may aid in the elucidation
of the molecular mechanisms that orchestrate the inflammatory response to IA rupture.
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Introduction
The rupture of an intracranial aneurysm (IA) resulting in a
subarachnoid hemorrhage (SAH) results in many systemic
effects and strongly influences the functioning of the immune
system. Alterations in inflammation-related protein levels in
peripheral blood and in the number and activity of immune
cells have been reported [1–3]. These changes are associated
with the systemic consequences of IA rupture, including in-
flammatory responses and immunodepression, which might
be critical for patient outcomes. The prognosis of SAH re-
mains poor for most patients, who suffer from high mortality
rates and long-term neuropsychological complications and de-
creased quality of life [4]. The molecular mechanisms under-
lying the systemic response to IA rupture are still insufficient-
ly understood. Their elucidation would be useful for the im-
provement of the treatment of SAH patients.
There is a growing body of evidence that indicates that non-
coding RNAs (ncRNAs) play a crucial role in many patholog-
ical conditions. Among the ncRNAs, microRNAs (miRNAs)
are the best-described class of posttranscriptional regulators.
These small molecules (18–25 nucleotides in length) result in
the posttranscriptional silencing of targeted protein-encoding
genes. Moreover, a single miRNA controls the expression of
multiple genes, and a single gene can be regulated by various
miRNAs. The role ofmiRNAs in pathologies related to cerebral
vessels seems to be beyond dispute [5–7].
Previously, we demonstrated that IA rupture induces a sys-
temic response associated with changes in the mRNA profiles
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in peripheral blood cells and the composition of mononuclear
cells, in an inhibition of lymphocyte responses and a concom-
itant enhancement of monocyte activity [8]. Here, we sought
to investigate the effects of IA rupture on the expression of
small ncRNAs in peripheral blood cells using deep tran-
scriptome sequencing. Moreover, we analyzed the levels of
selected inflammatory molecules, for which expression might
be regulated by miRNAs that were identified has having dif-
ferential expression in aneurysmal SAH. To assess the time-
related changes, patients in the acute and chronic phases of
SAH were included in the study.
Methods
Patients
Patients with ruptured IAs were prospectively recruited from
patients at the Department of Neurology or Neurosurgery and
Neurotraumatology, University Hospital, Krakow, as previ-
ously described [8]. Briefly, two independent SAH patient
groups were analyzed: acute (first 72 h after IA rupture) and
chronic (3–15 months after SAH). Control subjects (C) were
recruited from outpatients clinic patients who suffered from
headaches. However, they were not sampled during the acute
pain attack and they were not on a long-term specific anti-pain
medication. All subjects were free of any immune system-
affecting disorders (including autoimmunity and malignan-
cies) and immunomodulating drugs (including steroids and
immunosuppressants). Demographic and risk factor data were
collected. All subjects were Caucasian. Written informed con-
sent was obtained from all participants (or the guardians of
participants) before their inclusion in the study. The local
ethics committee approved the study.
The differences between the groups were analyzed using χ2
and Fisher exact tests or the Mann-Whitney U test where
appropriate. A p value <0.05 was considered statistically
significant.
Blood Collection and RNA Extraction
Venous whole blood was collected before neurosurgical inter-
vention in PAXgene Blood RNATubes (PreAnalytiX, GmbH,
Switzerland). The tubes were frozen and stored at −70 °C until
further processing. Total RNAwas purified from blood sam-
ples using a PAXgene Blood RNA Kit (PreAnalytiX) accord-
ing to the manufacturer’s protocol and was treated with
DNase. The RNA concentrations were measured using a
NanoDrop ND-1000 Spectrophotometer (NanoDrop
Technologies, Montchanin, DE), and the RNA quality was
determined by chip-based capillary electrophoresis utilizing
the Agilent RNA 6000 Nano Kit and an Agilent Bioanalyzer
2100 (Agilent, Palo Alto, CA) according to the manufacturer’s
protocols.
Small RNA Sequencing
Small RNA (sRNA) library preparation and sequencing were
performed with Illumina sequencing technology (Illumina,
San Diego, CA). The sRNA library was generated with the
TruSeq Small RNA Library Kit. Briefly, 3′ and 5′ adapters
were ligated to 1 μg of total RNA with T4 RNA ligase.
Then, reverse transcription was performed with Illumina
sRNA RT-Primer, and the cDNA was amplified by PCR
(11 cycles) using the Illumina sRNA primer set. The amplified
total cDNA library was purified and size-selected (insert size
22–30 bp) in a 6% Novex TBE gel. The transcriptome librar-
ies were sequenced on a HiSeq 2500™ (Illumina) with the
following parameters: SE50 (single end) and 10 M clean
reads; this provided a minimum of 500 Mb of raw data per
sample. The RNA-seq data were submitted to the NCBI
Sequence Read Archive (SRA): SRP150595.
Next-Generation Sequencing (NGS) Data Analysis
The sequence read quality was evaluated using the FastQC
(0.11.5) quality filter module. The raw reads were mapped to
the reference human genome hg38 using BWA (version
0.7.17). The expression levels were quantified using
IntersectBed (v2.28.0) and GTF with data from the miRbase
database (version 20) and the DASHR database of human
small noncoding RNAs in human tissues and cell types
(v2.0). sRNA transcripts with counts per million (CPM)
values above 2 in at least 10 samples were considered detect-
able and were used for further analysis. The statistical signif-
icance was analyzed using the edgeR package (v.3.6.8). The
false discovery rate (FDR) was estimated using the
Benjamini-Hochberg method. The paired samples t-test was
used to compare the means between the groups of samples (C
vs RAA, C vs RAC, RAA vs RAC). All statistical analyses
were performed using R software v3.4.3. Hierarchical cluster-
ing was performed using the measure of 1-correlation distance
metric and centroid distance linkage methods. Cluster visual-
ization was performed using dChip software v. 2010.01 (DOI:
https://doi.org/10.1186/1471-2105-9-231).
Functional Classification of Differentially Expressed
miRNAs
To identify the set of active biological pathways associated
with the miRNAs and their target genes, we applied stringent
statistical methods. The miRNA Enrichment Analysis and
Annotation Tool (miEAA) was used to identify overrepresent-
ed ontological groups within the set of regulated miRNAs and
to group them according to functional classifications [9]. The
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list of miRNAs identified by sRNA sequencing was used as
the input for the analysis. The statistical significance analysis
of miRNA enrichment was performed using the ORA algo-
rithm as implemented in the miEAA online resources.
Overrepresented categories were defined as having at least
10 miRNAs and an FDR adjusted p < 0.05.
miRNA Target Prediction
The prediction of molecular targets was performed to examine
miRNA-mediated regulation in a pathway-specific manner.
Genes included in the top pathway, which was cytokine-
cytokine receptor interactions (hsa04060), and the related
GO category cytokine activity (GO:0005125) were consid-
ered to be involved in immune responses and analyzed for
the presence of conserved sites that matched the seed regions
of the regulated miRNAs. A list of biologically predicted tar-
gets of differentially expressed miRNAs found in our study
was compiled using miRBase. Experimentally validated tar-
gets were considered along with predicted targets (Target
score > 60). To determine the possible miRNA-mRNA inter-
actions, the list of gene targets was compared with the list of
differentially expressed miRNA genes. The results of the gene
expression profiling were obtained from RNAseq of the total
transcriptome from the same patients [8].
Enzyme-Linked Immunosorbent Assay
The blood samples were collected at the same time as those
obtained for transcriptomics and were centrifuged within 1 h
of collection. Plasma was collected and stored at −80 °C until
use. Based on the miRNA profiling, the following cytokines
were selected: soluble Fas (sFas), soluble Fas ligand (sFasL),
and high mobility group box 1 protein (HMGB1). Their con-
centrations in plasma were determined using commercially
available ELISA kits; for sFas and sFasL, a Quantikine kit
(R&D Systems Inc., Minneapolis, MN) was used, and for
HMGB1 a kit from IBL International (Hamburg, Germany)
was used according to the manufacturer’s protocols. The intra-
and inter-assay coefficients were below 7%. All measure-
ments were performed in duplicate. The differences between
groups were examined using the Mann-Whitney U test, and
p < 0.05 was considered statistically significant.
Results
Alterations in sRNA Abundance Levels in Response
to IA Rupture
The study included 19 patients in the acute phase of IA rupture
(RAA, first 72 h), 20 patients in the chronic phase of SAH
(RAC, 3–15 months), and 20 controls. Their clinical
characteristics were previously described [8] and are briefly
summarized in Table 1. Ruptured IAwere located in the ante-
rior circulation in 17 RAA patients and 16 RAC patients.
During hospitalization, 4 patients in the RAA group devel-
oped infections (2 – pneumonia, 1 – urinary tract infection,
1 – sepsis), and 2 patients died.
We used NGS to comprehensively examine the expression
levels of sRNA derived from the peripheral blood. The nor-
malized miRNA abundance levels (CPM) were measured for
the sRNA transcripts annotated in the GRCm38.p13 genome
release. A total of 65,156 RNAs were analyzed, and the ex-
pression signal was detected for 17,930 transcripts. For 1766
sRNA genes, we detected abundance levels at the threshold
defined by CPM >2 (in at least 10 samples). When comparing
the RAA and RAC patients and the controls, we found 106
mature miRNAs and 90 miRNA precursors that were differ-
entially expressed between the groups (FDR <10% in edgeR).
In general, the profiles of the alterations are similar for the
precursors and the respective mature miRNAs. The pair-
wise comparisons and comparison of fold-change of differ-
ences between the groups (C vs RAA, C vs RAC, RAA vs
RAC) indicated that majority of changes when miRNA abun-
dance levels increased were detected in the acute phase. In the
chronic phase of IA rupture we revealed relatively more
downregulated miRNAs comparing to the acute phase
(Supplementary Table S1). We focused further analysis on
the miRNA expression profiles and the putative target genes.
Expression Profiles of miRNA Alterations in Peripheral
Blood Cells from Patients after IA Rupture
miRNAs are functionally well defined members of the small
ncRNA family. The presented analyses were based on the
functional annotations available for miRNAs. The list of reg-
ulated sRNAs contains 93 unique miRNAs (Supplementary
Table S1). Hierarchical clustering revealed three major pat-
terns in the miRNAs (A-C) altered in response to IA rupture
(Fig. 1).
The two main profiles of the alterations contain miRNAs
that are downregulated (pattern B with 42 miRNAs) and up-
regulated (pattern Cwith 39miRNAs) in the acute phase of IA
rupture. Both of these patterns return to normal levels (based
on the controls) in most patients in the chronic phase of IA
rupture. The additional small cluster profile consists of
miRNAs (pattern Awith 11 miRNAs) that are downregulated
in the chronic phase of IA rupture.
Also, we tested sample classification using the identified
signature of the regulated miRNAs. However, the distinction
between chronic phase of IA rupture and controls was limited.
Since the female patients were overrepresented in the RAC
group when compared to controls, we evaluated the potential
effect of this difference on expression of miRNAs. We iden-
tified 24 miRNAs that show sex-dependent (FDR 10%)
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expression profile in our dataset. One of the differentially
expressed miRNAs (miR-1307-5p) was also found on the list
of IA-rupture regulated miRNA (FDR 10%). However, the
effect of clinical status (RAA, RAC, C) was still significant
when sex factor was taken into account. Thus, we considered
that the difference in proportion of males and females between
the experimental groups did not have a major effect on the
profile of transcriptional alterations induced in response to IA
rupture.
Functional Annotation of the Regulated miRNAs
in Peripheral Blood Cells
To identify the functional associations of the miRNAs with
altered expression in response to IA rupture, we used enrich-
ment analysis. To characterize the transcriptional representa-
tion of biological processes, a list of 93miRNAswas analyzed
by using miRWalk annotations. Among the regulated
miRNAs, functional clusters connected to GO terms that in-
cluded receptor binding, the regulation of ubiquitin protein
ligase activity, and inflammatory responses (FDR corrected
p < 0.01) were overrepresented. The analysis of the enriched
signaling pathways revealed more specific functional connec-
tions. The analysis indicated that the miRNAs regulated after
IA rupture (for example, miR-142-3p, let-7f-5p, and miR-98-
5p) might be involved in cytokine-cytokine receptor interac-
tions (hsa04060 pathway, FDR corrected p < 0.01)
(Supplementary Table S2).
Gene Target Prediction for the Identified miRNAs
The analysis revealed that out of the 93 identifiedmiRNAs, 34
target cytokines that are regulated in response to IA rupture.
Twenty-three potential targets (with a Target score > 60) were
identified from the list of 215 genes that were involved in
cytokine activity (GO:0005125) and cytokine-cytokine recep-
tor interactions (hsa04060). The list of targets includes INHBB
(miR-22-3p, miR-148a-3p, miR-152-3p, and miR-22-3p),
CSF1 (miR-484), CXCL5 (miR-25-3p), HMGB1 (let-7a-3p,
let-7f-1-3p, miR-142-3p, miR-3529-3p, and miR-505-3p),
and FASLG (let-7a-5p, let-7c-5p, let-7e-5p, and miR-98-5p).
The mRNA abundance levels of the target genes HMGB1,
CXCL5, CSF1 and FASLG were decreased in patients in the
acute phase of IA rupture (RAA) in comparison to those in
control patients. The expression level of INHBB transcript was
increased in patients in that stage (Fig. 2).
Regulation of the Targeted Inflammatory Factors
For the analyses of the protein levels of identified potential
miRNA targets, we chose HMGB1 and sFasL. In addition, we
measured the sFas levels. Both sFas and sFasL showed sig-
nificantly decreased levels in SAH patients in comparison to
those in controls. In the acute phase, the levels were lower
than in the chronic period after IA rupture. The sFas/sFasL
ratio did not differ significantly between the analyzed groups.
In contrast, the HMGB1 concentration was significantly
higher in RAA patients than in control subjects, but no signif-
icant differences were observed between the RAA and RAC
groups. A summary of these data is presented in Fig. 3.
Search for Disease-Related miRNAs Altered
in Response to IA Rupture
To find clinical points of reference for our results, we com-
pared the lists of regulated miRNAs with previously reported
associations with disease etiology. We used the Human
MicroRNA Disease Database (HMDD), and we found that a
Table 1 Clinical characteristics






Median age, years (IQR) 54 (48–62) 50 (41–56) 55 (50–60)
Female, % 73.7 90.0 55.0*
Hypertension, % 57.9 55.0 50.0
Smoking, % 31.6 40.0 30.0
Excessive drinking, % 0 5.0 10.0
Diabetes mellitus, % 5.3 5.0 10.0
Hyperlipidemia, % 5.3 0 15.0
Admission Hunt-Hess score (IQR) 2 (1–3)
Admission WFNS score (IQR) 1 (1–3)
Admission GCS score (IQR) 15 (13–15)
RAA = acute phase of intracranial aneurysm (IA) rupture; RAC= chronic phase of IA rupture; C = control sub-
jects; IQR = interquartile range; GCS = Glasgow Coma Scale; WFNS =World Federation of Neurological
Surgeons
*p < 0.05 RAC vs C
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significant number of the identified miRNAs are associated
with clinical conditions related to immune system activity,
inflammatory responses, and cell cycle regulation. A function-
al analysis revealed that IA rupture is associated with the dys-
regulation of miRNAs involved in the etiology of cancer,
muscular disorders and heart failure (Supplementary
Table S3). Analysis of the pathological conditions known to
be linked to differentially expressed miRNAs (including hsa-
let-7c, hsa-let-7e, hsa-miR-98 and hsa-miR-142) indicated
that the common features of these conditions are the involve-
ment of the immune system, inflammatory responses, and cell
cycle regulation. The list of miRNAs associated with the dis-
eases contains several that target genes that encode cytokine-
related factors (let-7c, let-7e, miR-98 target FASLG, and miR-
142 targets HMGB1).
Discussion
Following IA rupture, we found significant changes in the
expression levels of several subclasses of small ncRNAs.
The most prominent effects of SAH were observed within
Fig. 1 Expression profiles of miRNAs in the peripheral blood cells of
patients after IA rupture. The differences in expression in samples from
subjects in the acute phase of IA rupture (RAA), the chronic phase of IA
rupture (RAC) and healthy controls (C) were analyzed by using small
RNAseq. The results are shown as a heatmap and include miRNAs with
genome-wide significance in terms of the clinical status factor (10%
FDR). The colored rectangles represent the transcript abundances of 93
miRNA measured in the samples described above (the list is included in
Supplementary Table S1). The expression profiles of the miRNAs are
hierarchically clustered using a 1-correlation distance metric and the cen-
troid linkage of nodes. Major miRNA transcription patterns are arbitrarily
described as ‘A’, ‘B’, and ‘C’. The intensity of the color is proportional to
the standardized values (between - 3 and 3) of each RNAseq measure-
ment, as indicated on the bar below the heatmap image. Blue-to-red
shades indicate increased relative expression; blue shades indicate re-
duced expression; white indicates median expression. The regulated
miRNAs linked to various molecular pathways and the disease etiology
are listed on the right. The presented miRNAs are linked to the top
enriched pathway (hsa04060 - cytokine-cytokine receptor interaction)
and/or associated with disease pathophysiology (based on the HMDD
database) [10]. The disease-related example miRNAs are connected to
at least four diseases in the top seven (Supplementary Table S2). The
threshold level for statistical significance for enrichment was set at an
FDR adjusted p < 0.05
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the first 72 h. This period is critical in SAH and is closely
related to early brain injury and neuroinflammation [11].
Here, we focused our analyses on miRNAs, which made up
the largest subgroup of regulated sRNAs. This category of
molecule is one of the best characterized. Although miRNAs
constitute a small part of the human genome, they regulate
most genes in a complex way. On the one hand, each
miRNA can target hundreds of mRNAs; on the other hand,
a single mRNA is often the target of multiple miRNAs [12].
Moreover, gene products may also influence miRNA expres-
sion. This kind of regulation is proposed for cytokines, during
which miRNAs target cytokinemRNA and cytokine signaling
in turn has an impact on miRNA expression [13].
Functional analyses of the regulated miRNAs revealed that
the differentially expressed miRNAs are generally involved in
processes related to inflammation, the immune system, the
cell cycle, cell death, and apoptosis. Such miRNAs were at
the top of lists of overrepresented regulated miRNAs com-
plied by using different tools, including WikiPathways,
Gene Ontology, and HDMM. This finding is consistent with
the results of other studies that investigated SAH by analyzing
changes in cellular activity, the transcriptome, or protein
levels. These studies showed that IA rupture causes obvious
dysregulation of both innate and adaptive immunity, which is
important for disease severity and outcome. Lopes et al.
investigated miRNA expression profiles in peripheral blood
in 27 aneurysmal SAH patients and 6 controls between 7 and
10 days after IA rupture. Among the 8 miRNAs identified as
differentially expressed between the SAH patients and con-
trols, 3 miRNAs, let-7f-5p, hsa-miR-451a, and hsa-miR-941,
were also found in our study and showed the similar expres-
sion changes [14]. In studies carried out in acute ischemic
stroke (IS), differentially expressed miRNAs in blood cells
were related to immune/inflammatory responses and the cell
cycle. This finding is consistent with our knowledge about the
effects of central nervous system injury on peripheral immune
system function. Bam et al. investigated IS patients in the first
48 h and found several miRNAs to be dysregulated that are
common in our RAA group, including hsa-miR-199b-3p, −
223, −30e, − 503, and − 550*. Among the top pathways
enriched for regulated miRNAs were those related to cancer,
hematological, and immunological diseases [15].
Additionally, Jickling et al. analyzed miRNA expression in
acute IS patients and found 8 differentially expressed
miRNAs that potentially regulate genes in pathways associat-
ed with inflammatory/immune responses [16]. The analysis of
pathways involved in the response to IA rupture might be
more important for a general understanding of the underlying
biological mechanisms rather than the examination of single
molecules. In particular, differences in study design and the
Fig. 2 Alterations in the transcript expression of the predicted target
genes for the identified miRNAs. The differences in gene expression
between the samples from subjects in the acute phase of IA rupture
(RAA), the chronic phase of IA rupture (RAC) and healthy controls (C)
were analyzed by using total RNA sequencing [8]. The mRNA abun-
dance levels of the target genesHMGB1, CXCL5, CSF1 and FASLGwere
analyzed in peripheral blood cells from patients after IA rupture. The
results are presented as relative expression levels (RPKM, reads per kb
per million reads) with the standard deviation (n = 19–20). Significant
primary effects based on analysis of variance with one-way ANOVA
for the clinical status factor (FDR # < 10%, ## < 1%, ### < 0.1%) are
indicated (Supplementary Table S3). Differences between the RAA,
RAC and C groups were analyzed using Tukey’s multiple comparisons
test (*p < 0.05, **p < 0.01, ***p < 0.001)
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methods used in different studies may make direct compari-
sons of the results at a single molecule level difficult.
Based on the results of the functional annotation, we fo-
cused our gene target prediction analysis on cytokines by tak-
ing advantage of the availability of mRNA expression data
from the same study subjects. Only mRNAs that showed dif-
ferential expression among the studied groups were investi-
gated [8]. Then, we measured the plasma protein levels for
selected molecules with known mRNA data. Therefore, we
chose sFasL and HMGB1 and the soluble form the receptor
for FasL, sFas.
The results of the protein measurements were surprising.
The abundance levels of miRNAs that probably control the
expression of FASLG and HMGB1 were increased, and the
mRNAs for these cytokines were downregulated in acute
SAH patients. Thus, one can expect decreased levels of pro-
tein products. This was true for sFasL but not for HMGB1.
FasL is a member of the tumor necrosis factor protein fam-
ily. It induces apoptosis in Fas-expressing cells and is an im-
portant death factor in the immune system [17]. It also plays a
role in inflammation by inducing the production of proinflam-
matory cytokines and neutrophil infiltration [18]. FasL can be
present in either a membrane-bound form (mFasL) on the cell
surface or a soluble form (sFasL), which is generated by the
cleavage of mFasL by matrix metalloproteinases [19]. These
forms play distinct roles; mFasL mediates apoptosis, whereas
sFasL has an anti-apoptotic function [18].
Fas is a receptor for FasL, and the Fas/FasL pathway is an
important regulator of apoptosis within the immune system.
For instance, activation-induced cell death in peripheral T
cells is mediated through the interaction of Fas and FasL
[20]. Likewise FasL there are different functional isoforms
of Fas that are generated by alternative splicing and are
expressed as soluble molecules (sFas) [21]. sFas prevents ap-
optosis by inhibiting the binding of Fas to FasL at the cell
surface [22]. Thus, the circulating sFas/sFasL system is an
important part of the apoptosis signaling pathway. Here, we
found the significant downregulation of both sFasL and sFas
proteins after IA rupture. The interpretation of these results is
unclear since we did not measure the expression of the
membrane-bound forms of these proteins. Thus, an unambig-
uous determination as to whether this represents pro- or
antiapoptotic activity is impossible. However, our results from
the flow cytometry analyses showed a significant decrease in
CD3+ Tcell counts (both CD4+ and CD8+) in the acute SAH
period in the same patients [8]. To the best of our knowledge,
there are no reports of the systematic study of the sFas/sFasL
system in SAH patients. Studies on IS provided different data.
Mahovic et al. found that sFas levels were higher in serum and
cerebrospinal fluid (CSF) in acute IS patients than in controls
[23]. In contrast, Tarkowski et al. repoerted decreased levels of
sFas in CSF [24]. In FasLmutant (gld) mice subjected to focal
brain ischemia, the percentage of CD4+ T cells in peripheral
blood was decreased when compared to that in wild-type an-
imals [25]. In a population-based Japanese study, higher se-
rum sFas levels were associated with higher mortality in SAH
[26].
In contrast, HMGB1 protein levels in plasma in the RAA
group were increased, whereasHMGB1mRNAwas downreg-
ulated in comparison with that in controls.
HMGB1 is a nonhistone DNA binding protein that is re-
leased following tissue injury from necrotic cells and serves as
a proinflammatory cytokine [27]. It is also recognized as a
damage-associated molecular pattern molecule (DAMP).
The results of studies on IS suggest the important role of
HMGB1 in stroke-induced immunosuppression, which is
similar to a phenomenon observed in SAH [28–31]. The
levels of this protein were increased in IS patients and corre-
lated with the number of circulating leukocytes, stroke sever-
ity, and inflammatory markers [32]. A recent meta-analysis of
28 studies comprising almost 2700 IS patients found signifi-
cantly increased circulating HMGB1 blood levels that were
correlated with stroke severity and infarct volume [33].
DAMPs, including HMGB1, can also initiate the inflammato-
ry response after IA rupture. In many studies, an increase in
HMGB1 levels in CSF SAH patients was found and was
shown to be positively correlated with worse outcomes [34,
35]. Higher plasma levels of HMGB1 in aneurysmal SAH
were associated with worse clinical status and poor prognosis
[36].
In the present study, the expression of HMGB1 at the
mRNA and protein levels was discordant.
One of the possible explanations could be the different
sources of particular molecules. RNAs were isolated from
Fig. 3 Plasma levels of sFasL, sFas, and HMGB1. *p < 0.05
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peripheral blood cells, whereas protein was measured in plas-
ma. Circulating HMGB1 can be released from various cells,
including activated platelets [31, 37]. The activation of plate-
lets is a known phenomenon in SAH and is associated with
early brain injury after SAH [3, 38]. Thus, one can speculate
that in the acute period after IA rupture, there is a tendency to
decrease the production of HMGB1 in peripheral leukocytes;
however, due to its release from other sources, including acti-
vated platelets, the plasma levels continue to rise.
Our study has some potential drawbacks. One is the rela-
tively limited sample size and the lack of validation of the
obtained results in another group of patients. However, in
most studies on miRNA expression, the numbers of included
subjects are similar. Although control group was recruited
among patients suffered from headaches, they were not sam-
pled during the acute episode of pain. Moreover, theywere not
on a specific anti-pain medication. Thus, we assumed that
obtained results can be generalized and the detected differ-
ences between studied groups are related to the IA rupture.
The results of the present study highlight the significance of
immune/inflammatory responses in IA rupture and are consis-
tent with previous reports from our group and others. In addi-
tion, we cannot sharply delineate which specific miRNA or
miRNA cluster plays a key role and which signaling pathway
is the most important during systemic reactions to SAH. This
study was designed to analyze changes in global expression
profiles to obtain more general insights into the peripheral
processes underlying the response to SAH. However, we did
not include in this study patients with unruptured IAs. Thus,
some of the transcriptomic changes may be related to the
presence of IA itself. We also analyzed the alterations in ex-
pression in peripheral leukocytes only. Thus, we cannot assess
the effects of IA rupture on the transcriptome in other cell
types that may also play important roles in the acute SAH
phase. However, considering that vessel wall cellular compo-
nents, including endothelium and vascular smooth muscle
cells, might be involved, human studies using that approach
are likely to be extremely difficult to conduct, if at all possible.
In summary, the results of this study demonstrated that IA
rupture influences the expression of miRNAs in peripheral
blood cells. The most highly regulated pathways are related
to inflammation and the immune response, especially those
related to cytokine processes. However, further studies are
warranted to clarify the roles of specific miRNAs in SAH
and to translate them into clinical applications.
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